XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
XCSport体育:Technology Platform
Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
XCSport体育:R&D Result
Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2026-06-03
Henlius Unveils Updated Phase 2 Results and Phase 3 Trial Design for Anti-HER2 mAb HLX22 in First-Line HER2+ Gastric Cancer
2026-06-01
Latest Results of Serplulimab in Lung and Gastrointestinal Cancer Released at ASCO 2025
2026-05-26
Henlius Receives Orphan Drug Designation for Its Innovative Anti-HER2 mAb HLX22 in the European Union for Gastric Cancer
2026-05-21
Henlius Strengthens Information Security with ISO/IEC 27001:2022 Certification Upgrade
2026-05-16
First Subject Dosed for Phase 1/3 Clinical Trial of Henlius’ Proposed Ipilimumab Biosimilar
2026-05-14
Henlius Included in MSCI Global Small Cap Indexes, Reinforcing Its Position in Global Capital Markets
2026-05-13
Henlius Will Be at BIO 2025
2026-05-08
Latest Results of Serplulimab in Gastric Cancer Released at IGCC 2025
2026-04-29
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
1
2
3
4
5
...
7